Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $17,485 | -$25,091 | -$58,573 | -$17,914 |
| Dep. & Amort. | $2,228 | $1,238 | $998 | $1,162 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $12,393 | $8,806 | $12,385 | $9,486 |
| Change in WC | $153 | $9,517 | -$29,049 | $9,718 |
| Other Non-Cash | -$788 | -$213 | $481 | $3,426 |
| Operating Cash Flow | $31,471 | -$5,743 | -$73,758 | $5,878 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$396 | -$15,000 | -$450 | -$627 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$35,272 | -$31,206 | -$28,894 | -$141,459 |
| Inv. Sales/Matur. | $39,700 | $41,650 | $101,228 | $62,050 |
| Other Inv. Act. | $98 | $259 | $893 | $0 |
| Investing Cash Flow | $4,130 | -$4,297 | $72,777 | -$80,036 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $19,950 | $19,542 | $0 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$10,000 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$1,641 | -$1,583 | -$12,992 | $62,675 |
| Financing Cash Flow | -$11,641 | $18,367 | $6,550 | $62,675 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $23,960 | $8,327 | $5,569 | -$11,483 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $32,786 | $24,459 | $18,890 | $30,373 |
| End Cash | $56,746 | $32,786 | $24,459 | $18,890 |
| Free Cash Flow | $31,075 | -$20,743 | -$74,208 | $5,251 |